FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Rel ...

Core Viewpoint - NeoGenomics is transitioning from a commodity diagnostic service provider to a comprehensive precision oncology platform, indicating a strategic shift in its business model to enhance its market position and service offerings [1]. Company Strategy - The company is focusing on leveraging first mover advantages in the minimal residual disease (MRD) monitoring sector, which is gaining significant attention in the oncology market [1]. Market Position - The shift towards a precision oncology platform suggests that NeoGenomics aims to differentiate itself from competitors by offering more specialized and advanced diagnostic services [1].

Company Overview - NeoGenomics is a healthcare company focused on providing diagnostic testing services for cancer patients, emphasizing the importance of their mission to improve patient outcomes [2][3] - The company has a dedicated team of over 2,500 employees who are passionate about their work and have a personal connection to cancer, which drives their commitment to the mission [2] Patient Impact - NeoGenomics recognizes the significant impact their services have on patients' lives during challenging times, highlighting the responsibility they feel to provide accurate and timely information to patients and their physicians [3] - The company aims to support patients in planning the right course of action based on the diagnostic information they provide [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

NeoGenomics FY Conference Summary Company Overview - **Company**: NeoGenomics (NasdaqCM:NEO) - **Industry**: Oncology diagnostics and lab services - **Focus**: Pure play in cancer testing, providing diagnostic services exclusively for oncology [4][5] Key Points and Arguments Market Position and Growth - NeoGenomics has established a market leadership position in hematology diagnostics, accounting for over **25%** of HEME testing across diagnostics and therapy selection [11] - The company has delivered **double-digit revenue growth** and **nine consecutive quarters** of positive adjusted EBITDA through Q3 of 2025 [5] - The oncology testing market is projected to grow significantly, with **one in two men** and **one in three women** expected to develop cancer in their lifetime [5][6] - NeoGenomics is poised to enter the **$20 billion-plus MRD market** with the launch of RaDaR-ST, which is expected to drive growth in 2026 and beyond [9][13] Strategic Pillars for Success 1. **Leverage Leadership in HEME**: Expand into solid tumor therapy selection and MRD markets [10] 2. **Evolve Offerings**: Meet the needs of pathologists and oncologists in community settings [10] 3. **Targeted Investments**: Drive top-line growth and margin expansion [10][17] Product Development and Launches - The company launched the **PanTracer family** for therapy selection, which has seen rapid growth in volumes, doubling from 2023 to 2024 and again from 2024 to 2025 [12] - RaDaR-ST has two approved indications for MolDX reimbursement, with additional submissions expected to double the patient eligibility for monitoring [13] - The introduction of **PanTracer liquid biopsy** is anticipated to follow a similar growth trajectory as the tissue assay, addressing gaps in the portfolio [36] Financial Performance - Preliminary Q4 revenue for 2025 is estimated at **$190 million**, representing **11% growth** year-over-year, with full-year revenue around **$727 million**, reflecting **10% growth** [21] - NGS revenue growth is projected at **22%** in 2025, indicating strong demand for next-generation sequencing products [18] Community Focus - Approximately **80%** of cancer treatment occurs in community settings, where NeoGenomics aims to provide NCI-level care through exceptional diagnostic testing [6][7] - The company has a **Net Promoter Score of 78**, indicating strong physician satisfaction and commitment to improving customer experience [14] Future Outlook - Growth drivers for 2026 include continued penetration of NGS, the launch of RaDaR-ST, and expansion into the northeast region through the acquisition of Pathline [22][23] - The company anticipates a balanced revenue contribution from both clinical and pharma segments, with a focus on clinical growth in the coming years [33] Additional Important Insights - NeoGenomics is focused on operational excellence, with a clear framework for product launches and customer engagement [31] - The partnership with Adaptive for heme MRD products is expected to enhance the portfolio and customer perception [41][42] - The company is preparing for the maturity of its **2028 convertible notes**, with plans to execute a strategy in 2026 [45][46] This summary encapsulates the key insights from the NeoGenomics FY Conference, highlighting the company's strategic focus, market position, and growth potential in the oncology diagnostics sector.

NeoGenomics (Nasdaq: NEO) JP Morgan Healthcare Conference Investor Presentation January 2026 Mission We save lives by improving patient care. Vision We are becoming the world's leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services. Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein ar ...

Core Viewpoint - AerCap Holdings has signed purchase and leaseback agreements with Virgin Atlantic for six new Airbus A330-900 aircraft, with deliveries scheduled from Q2 2026 to Q4 2027 [1][2]. Group 1: AerCap Holdings - AerCap is a global leader in aviation leasing, serving approximately 300 customers worldwide with a comprehensive fleet solution [3]. - The company is listed on the New York Stock Exchange (AER) and is headquartered in Dublin, with offices in various global locations [3]. Group 2: Virgin Atlantic - Virgin Atlantic, founded by Sir Richard Branson in 1984, emphasizes innovation and customer service, and was voted Britain's only Global Five Star Airline by APEX for nine consecutive years [4]. - The airline operates a leading transatlantic network in partnership with Delta Air Lines, offering connections to over 200 cities globally [5]. - Virgin Atlantic has committed to achieving Net Zero by 2050 and operates one of the youngest and most fuel-efficient fleets, with an average aircraft age under seven years [6].

Financial Results - NeoGenomics, Inc. announced preliminary unaudited financial results for Q4 and fiscal year 2025, with revenue figures yet to be disclosed[4] Executive Leadership Changes - The company is transitioning Mr. Jeffrey S. Sherman to the role of Executive Vice President, Finance, effective March 2, 2026, after his retirement[7] - Abhishek Jain has been appointed as Executive Vice President, Finance, effective January 12, 2025, and will become Chief Financial Officer on March 2, 2026[8] Compensation and Equity Grants - Mr. Jain's annual base salary is set at $520,000, with a target annual incentive bonus of 60% based on performance[9] - An initial equity grant for Mr. Jain is approved, amounting to $2,750,000, with 50% in restricted stock units and 50% in premium-priced stock options[9]

Core Insights - NeoGenomics, Inc. announced preliminary fourth quarter and full-year 2025 revenue, indicating a commitment to being the preferred cancer testing partner for pathologists and oncologists [2][6] - The company expects fourth quarter revenue of approximately $190 million, reflecting an 11% year-over-year growth, and full-year revenue of approximately $727 million, representing a 10% year-over-year growth [6] Revenue Summary - For the fourth quarter of 2025, NeoGenomics anticipates total revenue of around $190 million, which is an 11% increase compared to the previous year [6] - The projected total revenue for the full year 2025 is approximately $727 million, showing a 10% growth year-over-year [6] CFO Transition - NeoGenomics announced a succession plan for its Chief Financial Officer, with Abhishek Jain joining as Executive Vice President on January 12, 2026, and transitioning to CFO on March 2, 2026 [3][4] - Current CFO Jeff Sherman will retire on April 14, 2026, after ensuring a smooth transition [3][4] Leadership Insights - Abhishek Jain has a strong background in guiding life sciences companies through growth and transformation, and he aims to enhance financial discipline and operational efficiency at NeoGenomics [4] - Jeff Sherman expressed confidence in the company's ability to innovate in therapy selection and minimal residual disease (MRD) testing, particularly in community settings [4]

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified la ...